Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Validation of a Circulating Tumor Cell AR Therapy Resistance Assay in Men With Metastatic Castration Resistant Prostate Cancer (ARCTIC)

NCT06141993 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT06141993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06141993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Validation of a Circulating Tumor Cell AR Therapy Resistance Assay in Men With Metastatic Castration Resistant Prostate Cancer (ARCTIC)
Lead sponsor
Duke University
Phase
Observational
Overall status
Recruiting
Start date
May 13, 2024
Completion date
April 30, 2027
Enrollment
120 (estimated)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

castration-resistant prostate cancer, prostate adenocarcinoma, prostate cancer, prostate cancer metastatic